KR20170109527A - N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료 - Google Patents

N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료 Download PDF

Info

Publication number
KR20170109527A
KR20170109527A KR1020177015227A KR20177015227A KR20170109527A KR 20170109527 A KR20170109527 A KR 20170109527A KR 1020177015227 A KR1020177015227 A KR 1020177015227A KR 20177015227 A KR20177015227 A KR 20177015227A KR 20170109527 A KR20170109527 A KR 20170109527A
Authority
KR
South Korea
Prior art keywords
naca
administered
acid
months
intramuscularly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177015227A
Other languages
English (en)
Korean (ko)
Inventor
피터 에이 캄포치아로
다니엘 하트만
Original Assignee
더 존스 홉킨스 유니버시티
나쿠이티 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티, 나쿠이티 파마슈티컬스, 인코포레이티드 filed Critical 더 존스 홉킨스 유니버시티
Priority to KR1020227009489A priority Critical patent/KR20220039853A/ko
Publication of KR20170109527A publication Critical patent/KR20170109527A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/912—

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
KR1020177015227A 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료 Ceased KR20170109527A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227009489A KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076594P 2014-11-07 2014-11-07
US62/076,594 2014-11-07
PCT/US2015/059589 WO2016073931A1 (en) 2014-11-07 2015-11-06 Treatment of retinitis pigmentosa with n-acetylcysteine amide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009489A Division KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료

Publications (1)

Publication Number Publication Date
KR20170109527A true KR20170109527A (ko) 2017-09-29

Family

ID=55909913

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177015227A Ceased KR20170109527A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료
KR1020237036499A Pending KR20230152177A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료
KR1020227009489A Ceased KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237036499A Pending KR20230152177A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료
KR1020227009489A Ceased KR20220039853A (ko) 2014-11-07 2015-11-06 N-아세틸시스테인 아미드를 사용한 색소성 망막염의 치료

Country Status (11)

Country Link
US (2) US20180296503A1 (enExample)
EP (2) EP4000612A1 (enExample)
JP (5) JP2017533969A (enExample)
KR (3) KR20170109527A (enExample)
CN (2) CN108498495A (enExample)
AU (4) AU2015342831B2 (enExample)
BR (1) BR112017009584A2 (enExample)
CA (1) CA2967327C (enExample)
HK (1) HK1252822A1 (enExample)
RU (1) RU2711913C2 (enExample)
WO (2) WO2016073931A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
EP4000612A1 (en) 2014-11-07 2022-05-25 The Johns Hopkins University Treatment of retinitis pigmentosa with n-acetylcysteine amide
EP3218481B1 (en) 2014-11-11 2020-04-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
US10590073B2 (en) 2017-09-20 2020-03-17 Nacuity Pharmaceuticals, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US20190135741A1 (en) * 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
EP3713553A4 (en) * 2017-11-21 2021-08-04 The Johns Hopkins University COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISEASES
EP3823671B1 (en) * 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CN109096161B (zh) * 2018-08-24 2020-10-27 武汉远大弘元股份有限公司 一种n-乙酰半胱氨酸的制备方法
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
EP3908271A4 (en) 2019-01-11 2022-10-26 NaCuity Pharmaceuticals, Inc. N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT
EP3908341A4 (en) * 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
EP4093389A4 (en) * 2020-01-24 2024-02-21 NaCuity Pharmaceuticals, Inc. Prodrug for the treatment of disease and injury of oxidative stress

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340147A (en) 1965-06-28 1967-09-05 Mead Johnson & Co Amides of n-acylated cysteines
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
US5874468A (en) 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
WO2002100293A2 (en) 2001-06-13 2002-12-19 Webb-Waring Institute For Biomedical Research A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same
BE1014949A3 (fr) 2001-08-14 2004-07-06 Probiox Procede de detection de stress oxydant et trousse pour sa mise en oeuvre.
AU2003247144B2 (en) 2002-08-02 2007-11-29 Mor Research Applications Ltd. Treatment of multiple sclerosis with brain targeted anti oxidant compounds
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
JP2005350405A (ja) 2004-06-11 2005-12-22 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
CN101232877A (zh) * 2005-04-21 2008-07-30 格伦·A·戈尔茨坦 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
JP4840804B2 (ja) 2006-01-20 2011-12-21 学校法人慶應義塾 酸化ストレスの判定方法
US20110288134A1 (en) 2008-10-29 2011-11-24 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US20120150029A1 (en) 2008-12-19 2012-06-14 University Of Miami System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography
US9173423B2 (en) 2009-07-31 2015-11-03 The Iams Company Animal food kibble with electrostatically adhered dusting
WO2011044230A2 (en) 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
EP2397125A1 (en) 2010-06-15 2011-12-21 Histocell, S.L. Antioxidant composition
US20120142550A1 (en) 2010-12-06 2012-06-07 Zehnder James L Vanin 1 as a Peripheral Blood Oxidative Stress Sensor
WO2013138744A1 (en) 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
WO2013163545A1 (en) * 2012-04-26 2013-10-31 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US20130303436A1 (en) 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
US20150328337A1 (en) 2012-12-19 2015-11-19 The Johns Hopkins University Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
WO2015148880A1 (en) 2014-03-28 2015-10-01 Warner Babcock Institute for Green Chemistry Method for the preparation of n-acetyl cysteine amide
EP4000612A1 (en) 2014-11-07 2022-05-25 The Johns Hopkins University Treatment of retinitis pigmentosa with n-acetylcysteine amide
EP3218481B1 (en) 2014-11-11 2020-04-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
KR102414503B1 (ko) 2016-03-17 2022-06-29 티오제네시스 테라퓨틱스, 인크. 시스테아민의 조절 방출을 위한 조성물 및 시스테아민 민감성 장애의 전신 치료
US10590073B2 (en) 2017-09-20 2020-03-17 Nacuity Pharmaceuticals, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11612576B2 (en) 2017-09-20 2023-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
EP3684309A4 (en) 2017-09-22 2021-06-09 University of Florida Research Foundation DEVICES AND METHODS FOR REDUCING CYSTINE CRYSTALS IN VIVO
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
CA3078680A1 (en) 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
EP3713553A4 (en) 2017-11-21 2021-08-04 The Johns Hopkins University COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISEASES
CN108618993B (zh) 2018-07-16 2021-07-27 广东格烯生物科技股份有限公司 一种美白组合物及其制备方法和应用
WO2020102810A1 (en) 2018-11-16 2020-05-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive gel eye drop for ocular delivery of cysteamine
EP3908271A4 (en) 2019-01-11 2022-10-26 NaCuity Pharmaceuticals, Inc. N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT
EP3908341A4 (en) 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis

Also Published As

Publication number Publication date
AU2019261762B2 (en) 2021-06-10
RU2017119230A (ru) 2018-12-10
AU2024200436A1 (en) 2024-02-08
WO2016073829A2 (en) 2016-05-12
EP3214934A1 (en) 2017-09-13
AU2021225263B2 (en) 2023-11-02
AU2021225263A1 (en) 2021-09-30
JP2021193119A (ja) 2021-12-23
EP3214934A4 (en) 2018-06-20
KR20230152177A (ko) 2023-11-02
JP2023145734A (ja) 2023-10-11
RU2017119230A3 (enExample) 2018-12-10
KR20220039853A (ko) 2022-03-29
US12472157B2 (en) 2025-11-18
WO2016073931A1 (en) 2016-05-12
CA2967327A1 (en) 2016-05-12
JP2020023549A (ja) 2020-02-13
HK1252822A1 (zh) 2019-06-06
AU2015342831A1 (en) 2017-05-25
JP2017533969A (ja) 2017-11-16
RU2711913C2 (ru) 2020-01-24
AU2019261762A1 (en) 2019-11-28
CA2967327C (en) 2020-04-28
JP2025160381A (ja) 2025-10-22
AU2015342831B2 (en) 2019-09-12
EP4000612A1 (en) 2022-05-25
CN107426997A (zh) 2017-12-01
BR112017009584A2 (pt) 2017-12-26
WO2016073829A9 (en) 2016-06-23
US20180296503A1 (en) 2018-10-18
CN108498495A (zh) 2018-09-07
US20170333375A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
AU2021225263B2 (en) Treatment of retinitis pigmentosa with n-acetylcysteine amide
US11766413B2 (en) Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA)
US12458608B2 (en) N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
US20210228509A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
KR20230022975A (ko) 시스틴증의 치료
US20230381120A1 (en) Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170602

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181218

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200416

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210219

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211222

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210219

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200416

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211222

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20201016

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20181218

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220218

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220120

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211222

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20210219

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201016

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200416

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181218

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220322